ISRCTN12418979进行中（未招募）Unknown
COMET trial: Comparison of pleural mesothelioma evaluation using volume measurements with an artificial intelligence program to the mRECIST v1.1 criteria, a prospective trial
Antoni van Leeuwenhoek Hospital0 个研究点目标入组 52 人开始时间: 2024年1月15日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •1. Histology or cytology-proven non-resectable pleural mesothelioma
- •2. Age =18 years
- •3. Availability of a baseline CT thorax with contrast before the start of new systemic treatment with a slice increment of =3 mm on the CT scan
- •4. Availability of at least one follow-up scan (the lungs must be fully contained in the image)
排除标准
- •1. CT scans with lungs not fully imaged
- •2. No histology-proven pleural mesothelioma
研究者
相似试验
招募中
1 期
Optimising regulatory T cell depletion with cyclophosphamide in combination with chemotherapy for enhanced anti-tumour immunity in patients with non-small cell lung cancer (NSCLC) and malignant mesothelioma (MM).Malignant MesotheliomaNon small cell lung cancerCancer - Lung - MesotheliomaCancer - Lung - Non small cellACTRN12609000260224Sir Charles Gairdner Hospital33
已完成
不适用
Mesothelioma - Early versus Delayed ChemotherapyMesotheliomaCancerISRCTN16586512The Royal Marsden NHS Foundation Trust (UK)43
进行中（未招募）
1 期
Mesothelioma Stratified Therapy (MiST) - Including the following treatment arms: MiST 1 rucaparib MiST 2 abemaciclib MiST 3 pembrolizumab in combination with bemcentinib MiST 4 atezolizumab in combination with bevacizumabMalignant Mesothelioma (MM) - pleural and peritonealEUCTR2017-003353-41-GBniversity of Leicester120
已完成
2 期
Comparison of pleural effusion in Jackson-Pratt drain versus chest-tube after coronary artery bypass graft surgeryPleural effusion.Pleural effusion, not elsewhere classifiedIRCT201701193362N3Vice chancellor for research, Isfahan University of Medical Sciences194
终止
2 期
Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant MesotheliomaMesotheliomaNCT03644550National Cancer Institute (NCI)18